Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 1998

View Archived Issues

Company Profile: CpG ImmunoPharmaceuticals

Gliadel Wafer approved in Canada and France

Dura and Bristol-Myers Squibb sign exclusive license agreement

Shaman achieves favorable phase III results with diarrhea treatment in AIDS patients

Collaborative work by Janssen and Neurocrine Biosciences related to CRF antagonists

New 5-HT4 and/or H3 receptor ligands designed at Synthelabo

Agents for epilepsy, stroke and brain, spinal cord trauma in development at Novartis

Guilford patents NAALADase inhibitors for glutamate abnormalities, prostate conditions

Revolutionary drugs for Alzheimer's ready for human testing described by Nymox

In vivo safety and efficacy of photodynamic therapy evaluated by Theratechnologies in CML patients

Improvement in ischemia-reperfusion lung injury by treatment with FR-167653

Humanized anti-IL-6 antibody shows good efficacy and safety as rheumatoid arthritis Rx

Combination of PGE1 + rolipram or pentoxifylline shows potential for RA

Aged garlic extract: in vitro and in vivo antiallergic effects

First convincing data for extended therapeutic gene expression by human stem cells

Amgen's rights to NESP affirmed by arbitrator panel

Four-year drug target collaboration signed by PPD and RPR

Isis obtains antisense cancer rights from Genzyme Molecular Oncology

Astra and Schering-Plough sign new marketing agreements for several drugs

Pharmacokinetics of YJA-20379-8 not affected by water deprivation in rats

Hyseq presents gene product with potential application to vaccine development

U.S. patent issued for primate embryonic stem cells; Geron holds license

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...